Australia

Fujifilm’s Pharmaceuticals Business

NEW

We develop and provide pharmaceuticals that cover a wide range from diagnosis to treatment.

The content on this page is intended to healthcare professionals and equivalents.

Fusion of “Diagnosis” with “Treatment”
to deliver required drugs with appropriate dose to target site effectively

With improvement in living environment and the level of medical care, and populations aging worldwide in recent years, increased cases of cancer and cognitive impairment have become social serious issues.
Infection diseases are also expanding due to increasing movement of people globally and multiple types of drug-resistant bacteria.
It has been being revealed that many of those diseases have complex mechanisms to make pathology and progression different in relevant patients and are thus difficult to be effectively treated via standard of medical care.
 

As a total healthcare company, Fujifilm tries to address these issues with a unique approach that combines various technologies such as chemistry, biology, imaging, and artificial intelligence (AI) and thereby fusion of “diagnosis” with “treatment.”
 

Fujifilm also aims to realize medical care that truly improves patient quality of life (QOL) by establishing mechanisms that “to deliver required drugs with appropriate dose to target site effectively” through target-based drug discovery and development of radiopharmaceuticals and drug delivery system (DDS) as well.

This will simultaneously provide various effects including improved burden of medical costs resulting from the improvement of drug safety and the reduction of unnecessary drug treatment.

Change medical care and the society as well by changing the ideal pharmaceuticals—the vision of Fujifilm’s pharmaceutical business.

Conventional Standard Medical Treatment

Pharmaceutical Business of Fujifilm Group

Examples of Fusion of “Diagnosis” with “Treatment”

(1) Drug Development for Alzheimer's Disease Based on a Combination of Diagnostic Agents and AI

In drug development of Alzheimer's disease, an important approach is to improve success rate of clinical trials by accurately understanding individual disease conditions and checking individual administration of appropriate drugs.  Fujifilm supports accurate diagnosis of individual patients with radiopharmaceuticals that visualize amyloid β. At the same time, Fujifilm develops AI technology that predicts the progression of Alzheimer's disease through combining unique imaging technologies to analyze brain images and measure atrophy rates of respective regions in brain, with a database of multimodal health information. We are trying to improve the quality of clinical trials, and thereby promote success of drug development for Alzheimer's disease through the combination of diagnostic agents and AI.

(2) Administration of an Antibacterial Agent Specific to a Bacterial Strain Identified with In Vitro Diagnosis

In recent years, frequent uses of broad-spectrum antibacterial agents have have caused a worldwide problem due to the development of bacteria and viruses with antimicrobial resistance (AMR) worldwide. Fujifilm seeks to realize target-based therapy to ensure treatment with antibacterial agents specific to bacterial strains in infected patients that are precisely identified with in vitro diagnostic systems of the Fujifilm Group. Fujifilm aims to improve effectiveness of treatment, and restrict the spread of AMR resulting from attack on non-target bacterial strains.

A shift from “nonspecific therapy” to “target-based therapy”

(3) Assessment of Effectiveness of Radiopharmaceuticals in Advance for the Treatment of Cancers (Theranostics)

Administered a radiodiagnostic agent combined an antibody targeting a protein over-expressed on the specific cancer cells with a radioisotope (RI) in order to capture the radiation from the body as images and confirm the level of accumulation in cancer through the analysis of the images. If sufficient accumulation is confirmed, a treatment agent combined with another RI that attacks the cancer cells, a radiotherapeutic agent, is administered to directly work against the cancer in vivo.

Product lineup

Provides small molecular drugs, radiopharmaceuticals, contrast agents, and diagnostic adjuvants.

Provides contrast agents (generic drugs).

Provides clinical reagents (in vitro diagnostics).